Guangzhou Hexin Instrument Hits Day Low Amid Price Pressure, Shares at CNY 121.60

Guangzhou Hexin Instrument Co., Ltd. experienced a significant decline today, with the stock dropping by 5.65% and reaching an intraday low of CNY 121.60. This performance stands in contrast to the China Shanghai Composite, which fell by only 1.26% on the same day. Over the past week, Guangzhou Hexin has seen a more pronounced downturn, with a 13.07% decrease, while the broader index showed a slight gain of 0.41%. Despite a strong annual performance of 73.48%, the company has faced challenges in recent quarters, reporting negative results for two consecutive periods. Key financial metrics indicate a concerning trend, with a pre-tax profit of CNY -22.89 million and a net profit of CNY -18.74 million, reflecting substantial declines. The company's debt-to-equity ratio stands at 0.61, suggesting a high level of leverage. In the context of the pharmaceuticals and biotechnology industry, Guangzhou Hexin's long-term growth appears weak, with net sales declining at an annual rate of 21.81% over the last five years. As the company navigates these financial hurdles, its market position remains under scrutiny.